US · GOVX · BIOTECHNOLOGY
GeoVax Labs, Inc. (GOVX) intrinsic value and stock valuation
$1.81as of 2026-11-21 · Mkt cap 5.47M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
GeoVax Labs, Inc. DCF and intrinsic value
InvestorsCraft values GOVX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GOVX’s statements →
GeoVax Labs, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.49M | $3.95M | $0.00 | $80K | $390K |
| Operating income | -$-21.64M | -$-25.14M | -$-26.74M | -$-14.03M | -$-18.75M |
| Net income | -$-21.46M | -$-24.99M | -$-25.97M | -$-14.02M | -$-18.57M |
| EPSd | -$-22.35M | -$-119M | -$-259.7M | -$-140.2M | -$-185.7M |
| Operating cash flow | -$-21.47M | -$-24.68M | -$-25.17M | -$-19.03M | -$-11.2M |
| Capital expenditure | -$-30K | -$-20K | -$-50K | -$-130K | -$-50K |
| Free cash flow | -$-21.5M | -$-24.7M | -$-25.22M | -$-19.16M | -$-11.24M |
| Total assets | $6.34M | $8.16M | $9.28M | $31.4M | $11.8M |
| Total debt | $840K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$-2.24M | -$-5.51M | -$-6.45M | -$-27.61M | -$-11.42M |
| Total equity | $3.83M | $5.05M | $5.76M | $26.6M | $4.36M |
| Cash and short-term investments | $3.09M | $5.51M | $6.45M | $27.6M | $11.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.49M | $3.95M | $0.00 | $80K | $390K |
| Cost of revenue | $18.1M | $100K | $20.7M | $9.12M | $15.6M |
| Gross profit | -$-15.63M | $3.86M | -$-20.72M | -$-9.04M | -$-15.17M |
| Research and development expenses | $18.1M | $23.7M | $20.7M | $9.12M | $15.6M |
| Selling, general and administrative expenses | $6.01M | $5.39M | $5.95M | $4.99M | $3.58M |
| Other expenses | -$-18.12M | -$-100K | -$-20.65M | -$-9.12M | -$-15.55M |
| Operating expenses | $6.01M | $29M | $6.02M | $4.99M | $3.58M |
| Cost and expenses | $24.1M | $29.1M | $26.7M | $14.1M | $19.1M |
| Interest income | $170K | $170K | $780K | $10K | $0.00 |
| Interest expense | $0.00 | $20K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $70K | $100K | $70K | $60K | $40K |
| Ebitda | -$-21.4M | -$-24.88M | -$-25.89M | -$-13.96M | -$-18.53M |
| Operating income | -$-21.64M | -$-25.14M | -$-26.74M | -$-14.03M | -$-18.75M |
| Total other income/expenses, net | $170K | $150K | $780K | $10K | $180K |
| Income before tax | -$-21.46M | -$-24.99M | -$-25.97M | -$-14.02M | -$-18.57M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-21.46M | -$-24.99M | -$-25.97M | -$-14.02M | -$-18.57M |
| Weighted average shares outstanding | $960K | $210K | $100K | $100K | $100K |
| Weighted average diluted shares outstanding | $960K | $210K | $100K | $100K | $100K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.09M | $5.51M | $6.45M | $27.6M | $11.4M |
| Net receivables | $0.00 | $660K | $0.00 | $0.00 | $50K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $5.31M | $7.93M | $7.89M | $28.9M | $11.6M |
| Property, plant and equipment, net | $940K | $150K | $210K | $2.41M | $160K |
| Goodwill and intangible assets | $50K | $60K | $70K | $80K | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.03M | $220K | $1.4M | $2.41M | $170K |
| Total assets | $6.34M | $8.16M | $9.28M | $31.4M | $11.8M |
| Accounts payable | $790K | $1.85M | $2.8M | $1.75M | $2.06M |
| Short-term debt | $260K | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.94M | $3.11M | $3.52M | $4.75M | $5.44M |
| Long-term debt | $580K | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $580K | $0.00 | $0.00 | $0.00 | $2M |
| Capital lease obligations | $840K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $2.52M | $3.11M | $3.52M | $4.75M | $7.43M |
| Common stock | $0.00 | $10K | $0.00 | $30K | $10K |
| Retained earnings | -$-150.82M | -$-129.36M | -$-104.36M | -$-78.4M | -$-64.38M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $3.83M | $5.05M | $5.76M | $26.6M | $4.36M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $840K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$-2.24M | -$-5.51M | -$-6.45M | -$-27.61M | -$-11.42M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-21.46M | -$-24.99M | -$-25.97M | -$-14.02M | -$-18.57M |
| Depreciation and amortization | $70K | $100K | $70K | $60K | $40K |
| Stock-based compensation | $0.00 | $530K | $1.07M | $900K | $370K |
| Change in working capital | -$-1.19M | -$-310K | -$-360K | -$-5.97M | $6.93M |
| Accounts receivable | $660K | -$-660K | $0.00 | $50K | $130K |
| Inventory | $0.00 | $0.00 | $0.00 | -$-50K | -$-130K |
| Accounts payable | -$-1.47M | -$-410K | -$-1.23M | -$-2.69M | $6.81T |
| Net cash provided by operating activities | -$-21.47M | -$-24.68M | -$-25.17M | -$-19.03M | -$-11.2M |
| Investments in property, plant and equipment | -$-30K | -$-20K | -$-50K | -$-130K | -$-50K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-30K | -$-20K | -$-50K | -$-130K | -$-50K |
| Common stock issued | $19.1M | $21.4M | $4.06M | $27.7M | $9.41M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $19.1M | $23.8M | $4.06M | $35.4M | $12.8M |
| Net change in cash | -$-2.42M | -$-950K | -$-21.16M | $16.2M | $1.54M |
| Cash at end of period | $3.09M | $5.51M | $6.45M | $27.6M | $11.4M |
| Operating cash flow | -$-21.47M | -$-24.68M | -$-25.17M | -$-19.03M | -$-11.2M |
| Capital expenditure | -$-30K | -$-20K | -$-50K | -$-130K | -$-50K |
| Free cash flow | -$-21.5M | -$-24.7M | -$-25.22M | -$-19.16M | -$-11.24M |
Line items
Line items
Line items
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
- CEO
- David Alan Dodd
- Employees
- 19
- Beta
- 3.67
Explore
Frequently asked questions
What is the intrinsic value of GeoVax Labs, Inc. (GOVX)?
InvestorsCraft does not currently publish an intrinsic value for GOVX. How the IC value is calculated.
Is GOVX undervalued?
InvestorsCraft does not publish an undervaluation signal for GOVX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.